BriaCell Therapeutics (BCT.TO), up 1.6% in U.S. pre-market trading, is developing Bria-OVA+, its personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer, the company said on Friday.
The company has licensed ovarian cancer cell-lines from American Type Culture Collection (ATCC) and has begun development activities to support production of Bria-OVA+ for potential clinical use.
"Following the encouraging efficacy and tolerability data from BriaCell's Phase 2 study in metastatic breast cancer, we are expanding our pipeline to include cell-based immunotherapy candidates for gynecologic cancers beginning with ovarian," said Dr. William Williams, BriaCell chief executive officer.
"Bria-OVA+ reflects our broader strategy to build on the Bria-OTS+ platform and advance next-generation personalized immunotherapies for difficult-to-treat cancers and become a leader in women's health," he added.
BriaCell shares are up US$0.065, to US$4.115 in New York trading.